Actio Biosciences Inc.
- Biotech or pharma, therapeutic R&D
Actio Biosciences is a clinical stage biotech company pursuing genetically validated targets for rare diseases and then identifying expansion opportunities in more common diseases with shared underlying biology.
Actio has two lead small molecule programs. ABS-1230 is a KCNT1 inhibitor in IND-enabling studies for KCNT1-related epilepsy, a rare, devastating genetic epilepsy with no effective therapies. The second program is ABS-0871, an inhibitor of TRPV4, the genetic cause of Charcot Marie Tooth Disease Type 2C, a rare, disabling neuropathy with no effective therapies. Each program has >$1B in revenue potential in these core indications, driven by the severity of these diseases, the lack of therapeutic alternatives and by their disease modifying potential.
In addition, Actio has identified indication expansion opportunities for ABS-1230 in other developmental and epileptic encephalopathies and for ABS-0871 in overactive bladder, which could unlock substantial additional value.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}